ACCL vs HBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 24, 2026

ACCL

53.6
AI Score
VS
ACCL Wins

HBIO

52.8
AI Score

Investment Advisor Scores

ACCL

54score
Recommendation
HOLD

HBIO

53score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ACCL HBIO Winner
Forward P/E 0 15.0602 Tie
PEG Ratio 0 1.3059 Tie
Revenue Growth 1.0% -4.7% ACCL
Earnings Growth -84.0% -80.3% HBIO
Tradestie Score 53.6/100 52.8/100 ACCL
Profit Margin 11.3% -11.4% ACCL
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

ACCL 1M: +32.7% · 3M: +48.7% HBIO 1M: +0.8% · 3M: -4.4%

Current Technical Phase

ACCL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (13.8% over 20 days), RSI 76

RSI (14): 75.8 · Price: $2.23

HBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.1 · Price: $6.10

Fundamentals Snapshot

Metric ACCL HBIO
Market Cap
Forward P/E 0.0 13.9
Trailing P/E 55.4
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.4% 0.6%
Operating Margin 0.0% 0.0%
EPS 0.04 -2.15
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ACCL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.